Publications by authors named "Kim Howe"
Article Synopsis
- This study focuses on analyzing dopaminergic loss in patients with mild cognitive impairment with Lewy bodies (MCI-LB) using repeat SPECT imaging, comparing it to those with MCI due to Alzheimer’s disease (MCI-AD) and healthy controls.
- Researchers found a significant annual decline in dopamine binding in MCI-LB patients, while MCI-AD and control groups showed minimal changes.
- Results suggest that individuals with MCI-LB may experience noticeable changes in brain function over time, and the average time for a normal scan to show abnormalities is approximately six years.*
Objective: To provide evidence that cardiac I-123-metaiodobenzylguanidine sympathetic innervation imaging (MIBG) scintigraphy differentiates probable mild cognitive impairment with Lewy bodies (MCI-LB) from mild cognitive impairment due to Alzheimer disease (MCI-AD), we scanned patients with MCI and obtained consensus clinical diagnoses of their MCI subtype. We also performed baseline FP-CIT scans to compare the accuracy of MIBG and FP-CIT.
Methods: We conducted a prospective cohort study into the accuracy of cardiac MIBG scintigraphy in the diagnosis of MCI-LB.
Background: Dopaminergic imaging is an established biomarker for dementia with Lewy bodies, but its diagnostic accuracy at the mild cognitive impairment (MCI) stage remains uncertain.
Aims: To provide robust prospective evidence of the diagnostic accuracy of dopaminergic imaging at the MCI stage to either support or refute its inclusion as a biomarker for the diagnosis of MCI with Lewy bodies.
Method: We conducted a prospective diagnostic accuracy study of baseline dopaminergic imaging with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computerised tomography (123I-FP-CIT SPECT) in 144 patients with MCI.
Introduction: Some studies report that assessing regional I-cardiac MIBG uptake can aid in the diagnosis of Lewy body disease, but others report heterogeneity in healthy controls. We aimed to evaluate regional cardiac MIBG uptake patterns in healthy older adults and patients with dementia.
Methods: 31 older adults with normal cognition, 15 Alzheimer's disease (AD), and 17 Dementia with Lewy bodies (DLB) patients were recruited.
Article Synopsis
- Cardiac I-MIBG imaging is effective for diagnosing dementia with Lewy bodies, and this study compared different analysis methods to determine best practice among various patient groups.
- The study included 48 participants (17 with Lewy body dementia, 15 with Alzheimer's, and 16 controls) and found significant differences in heart-to-mediastinum ratios (HMR) when using different region sizes, but overall accuracy remained similar across methods.
- The results showed that fixed circular regions, particularly 6 cm in diameter, resulted in less variability and better placement, and HMR analysis proved to be more accurate than visual assessment alone.
Objective: I-123-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (FP-CIT) imaging is an established biomarker used in the diagnosis of Lewy body disease. Images are often reported with the aid of striatal binding ratios (SBRs), comparing uptake to a normal database via Z scores. It is well known that SBRs are age dependent.
View Article and Find Full Text PDFObjective: This study aims to explore the normal reference values for thyroid uptake of technetium-99m (Tc) pertechnetate in a UK population.
Patients And Methods: A retrospective review of 60 euthyroid patients who underwent thyroid imaging with Tc pertechnetate between January 2012 to April 2014 as part of dual-tracer subtraction parathyroid scintigraphy. Tc pertechnetate thyroid uptake values were determined for each patient.